Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Results of a 102 week Phase III investigation for linagliptin (trade name Trajenta? in Europe) were announced today, and showed significant and durable reductions in blood glucose levels for adults who suffer from type 2 diabetes. The study which was presented at the 47th Annual Meeting of the European Association for the Study of Diabetes (EASD), demonstrated that the DPP-4 inhibitor linagliptin displayed a promising safety profile and reduced HbA1c levels by 0.8% over the long term in individuals treated with linagliptin for the entire investigation period.
http://www.medicalnewstoday.com/articles/234596.php
http://www.medicalnewstoday.com/articles/234596.php